[go: up one dir, main page]

FI971527A0 - Indolijohdannaisten käyttö erilaisten sairauksien hoitoon - Google Patents

Indolijohdannaisten käyttö erilaisten sairauksien hoitoon

Info

Publication number
FI971527A0
FI971527A0 FI971527A FI971527A FI971527A0 FI 971527 A0 FI971527 A0 FI 971527A0 FI 971527 A FI971527 A FI 971527A FI 971527 A FI971527 A FI 971527A FI 971527 A0 FI971527 A0 FI 971527A0
Authority
FI
Finland
Prior art keywords
treatment
various diseases
migraine
indole derivatives
headache
Prior art date
Application number
FI971527A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI971527L (fi
Inventor
Kathryn Louise Monkhouse
Paul Gupta
Shirley Jones
Juan Lahuerta
Gillian Christine Land
Susan Frances Robson
Gillian Mary Ryder Samuels
Alan Brian Wilson
Martin James Wythes
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of FI971527A0 publication Critical patent/FI971527A0/fi
Publication of FI971527L publication Critical patent/FI971527L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI971527A 1994-10-12 1997-04-11 Indolijohdannaisten käyttö erilaisten sairauksien hoitoon FI971527L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9420529A GB9420529D0 (en) 1994-10-12 1994-10-12 Indoles
PCT/EP1995/003965 WO1996011685A2 (en) 1994-10-12 1995-10-05 Use of indole derivatives for the treatment of various diseases

Publications (2)

Publication Number Publication Date
FI971527A0 true FI971527A0 (fi) 1997-04-11
FI971527L FI971527L (fi) 1997-04-11

Family

ID=10762708

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971527A FI971527L (fi) 1994-10-12 1997-04-11 Indolijohdannaisten käyttö erilaisten sairauksien hoitoon

Country Status (25)

Country Link
US (2) US6455567B1 (pt)
EP (1) EP0785781B1 (pt)
JP (2) JP3096306B2 (pt)
KR (1) KR970705992A (pt)
CN (1) CN1160347A (pt)
AT (1) ATE210980T1 (pt)
AU (1) AU3699795A (pt)
BR (1) BR9504375A (pt)
CA (1) CA2202484C (pt)
CO (1) CO4480025A1 (pt)
CZ (1) CZ285633B6 (pt)
DE (1) DE69524780T2 (pt)
DK (1) DK0785781T3 (pt)
ES (1) ES2167465T3 (pt)
FI (1) FI971527L (pt)
GB (1) GB9420529D0 (pt)
HU (1) HUT77317A (pt)
IL (1) IL115530A (pt)
MX (1) MX9702732A (pt)
NO (1) NO971606L (pt)
PE (1) PE47296A1 (pt)
PL (1) PL319868A1 (pt)
PT (1) PT785781E (pt)
WO (1) WO1996011685A2 (pt)
ZA (1) ZA958557B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9424471D0 (en) * 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
WO2001052876A1 (en) * 2000-01-18 2001-07-26 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
AR035651A1 (es) * 2000-07-28 2004-06-23 Univ Madrid Complutense Uso de derivados de indol para la manufactura de un medicamento para reducir la presion intraocular y una composicion
ES2172415B2 (es) 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
EP1452167A1 (de) * 2003-02-28 2004-09-01 Cognis France S.A. Kosmetische, pharmazeutische und/oder dermatologische Zubereitungen enthaltend einen Extrakt aus Eperua falcata
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
DE10337184A1 (de) * 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
US9789161B2 (en) 2006-04-28 2017-10-17 Warsaw Orthopedic, Inc. Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin
US8916611B2 (en) * 2006-04-28 2014-12-23 Warsaw Orthopedic, Inc. Pharmaceutical removal of neuronal extensions from a degenerating disc
US20070253960A1 (en) * 2006-04-28 2007-11-01 Josee Roy Pharmaceutical removal of vascular extensions from a degenerating disc
CN103479624B (zh) * 2013-10-10 2015-06-17 嵊州市诺米克进出口有限公司 Racemosins A在制备治疗或预防口腔溃疡药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
GB2222768B (en) * 1988-06-17 1992-01-22 Nat Res Dev Analgesic compounds and compositions
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5578612A (en) 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559246A (en) 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
JP2575272B2 (ja) * 1990-10-15 1997-01-22 フアイザー・インコーポレイテツド インドール誘導体
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
ES2143992T3 (es) 1991-11-25 2000-06-01 Pfizer Derivados de 5-(hetero- o carbociclilamino)-indol, su preparacion y uso como 5-ht1 agonistas.
US5409941A (en) 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
TW288010B (pt) 1992-03-05 1996-10-11 Pfizer
GB9207396D0 (en) * 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
CA2133413C (en) 1992-04-07 2001-04-10 John Eugene Macor Indole derivatives as 5-ht1 antagonists
US5498626A (en) 1992-04-10 1996-03-12 Pfizer Inc. Acylaminoindole derivatives as 5-ht1 agonists
GB9207930D0 (en) 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) 1992-04-14 1992-05-27 Pfizer Ltd Indoles
TW251284B (pt) 1992-11-02 1995-07-11 Pfizer
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
DE69400824T2 (de) 1993-04-22 1997-03-13 Pfizer Research And Development Co., N.V./S.A., Dublin Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne
GB9317096D0 (en) 1993-08-17 1993-09-29 Pfizer Ltd Indoles
CZ59996A3 (en) 1993-08-31 1996-06-12 Pfizer 5-arylindole derivatives per se and for treating diseases, intermediates for their preparation and pharmaceutical compositions based thereon
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420503D0 (en) 1994-10-11 1994-11-23 Pfizer Ltd Therapeutic agents
GB9424471D0 (en) 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis

Also Published As

Publication number Publication date
CA2202484C (en) 2001-12-18
NO971606D0 (no) 1997-04-08
MX9702732A (es) 1997-06-28
AU3699795A (en) 1996-05-06
EP0785781B1 (en) 2001-12-19
JP3096306B2 (ja) 2000-10-10
JP2000080036A (ja) 2000-03-21
IL115530A (en) 2001-03-19
ATE210980T1 (de) 2002-01-15
US20030055098A1 (en) 2003-03-20
DE69524780T2 (de) 2002-06-13
NO971606L (no) 1997-04-08
PE47296A1 (es) 1996-11-12
ZA958557B (en) 1997-04-11
CZ285633B6 (cs) 1999-10-13
FI971527L (fi) 1997-04-11
PT785781E (pt) 2002-04-29
CA2202484A1 (en) 1996-04-25
ES2167465T3 (es) 2002-05-16
JPH09511755A (ja) 1997-11-25
CZ111897A3 (cs) 1998-06-17
PL319868A1 (en) 1997-09-01
DK0785781T3 (da) 2002-03-18
GB9420529D0 (en) 1994-11-30
US6455567B1 (en) 2002-09-24
BR9504375A (pt) 1997-04-08
WO1996011685A3 (en) 1996-08-15
EP0785781A2 (en) 1997-07-30
DE69524780D1 (de) 2002-01-31
HUT77317A (hu) 1998-03-30
CN1160347A (zh) 1997-09-24
KR970705992A (ko) 1997-11-03
CO4480025A1 (es) 1997-07-09
IL115530A0 (en) 1996-05-14
WO1996011685A2 (en) 1996-04-25

Similar Documents

Publication Publication Date Title
IL160028A (en) Thiophene carboxamide derivatives, process for their preparation, pharmaceutical compositions comprising them and their use in therapy
FI971527A0 (fi) Indolijohdannaisten käyttö erilaisten sairauksien hoitoon
DK0513702T3 (da) Melatoninderivater til anvendelse til behandling af søvnlidelser og til præ-anæstetisk medicinering
NO20045656L (no) Oftalmologisk anvendelse av roflumilast for behandlingen av oyesykdommer
AU2002359164A8 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
NO306464B1 (no) Benzimidazolforbindelser, farmasöytiske preparater som omfatter slike forbindelser, samt anvendelse av forbindelsene for fremstilling av medikamenter
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
KR910015300A (ko) 부스피론 : 수면 무호흡증의 치료용도
NO982863L (no) Nye forbindelser med analgetisk effekt
SE9702716D0 (sv) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
IT1276462B1 (it) Diamidi aromatiche acide ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico
PT1082116E (pt) Utilizacao de derivados de 4-piperidinometanol no tratamento de desordens do neurodesenvolvimento
ATE186215T1 (de) Verwendung von n-(pyridinyl)-1h-indol-1-aminen zur herstellung eines medikamentes zur behandlung von zwangsneurotischen erkrankungen
NO307406B1 (no) Anvendelse av 1-aryl-3-(4-piperidyl)-indolderivater ved behandling av kognitive forstyrrelser
ECSP951549A (es) Nuevo procedimiento de tratamiento
FI103970B1 (fi) Menetelmä kivun lievittämiseen sekä ihotautien ja muistin toimintahäiriöiden hoitoon tarkoitettujen 3-(1,2-bentsisoksatsol-3-yyli)-4-pyridiiniamiinien ja näiden johdannaisten valmistamiseksi
NO20020475L (no) 2-aminotetralinderivater for terapi av glaukom
RU97108290A (ru) Использование производных индола для лечения различных заболеваний, новый способ лечения
ATE247963T1 (de) Medikament zur behandlung von glaukoma und ischämischer retinopathie
EA200601270A1 (ru) Новые индено[2,1-a]индены и изоиндоло[2,1-a]индолы